Clinical trial
Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide
NCT00463983 · Institut National de la Santé Et de la Recherche Médicale, France, Other · Completed
Key facts
| NCT number | NCT00463983 |
|---|---|
| Title | Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide |
| Official title | Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis |
| Acronym | FIBROSAND |
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | octreotide |
| Enrollment | 25 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | Apr 20, 2007 |
| Last update posted | Mar 5, 2025 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: